Oligosaccharide Mixture for NEC Prevention in Infants
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current compositions fail to effectively prevent and treat necrotizing enterocolitis in infants and young children, and promote enteral feeding tolerance and gastrointestinal functional maturation, with existing probiotics and oligosaccharides showing inconsistent results and a need for specific formulations that are safe, easy to deliver, and cost-effective.
Innovation Solution
A composition comprising a mixture of specific human milk oligosaccharides, including 40-80 wt% fucosylated oligosaccharides, 10-50 wt% N-acetylated oligosaccharides, 5-40 wt% sialylated oligosaccharides, and 0-20 wt% precursors, which acts synergistically to protect the gut, promote maturation, and reduce inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If probiotics are used to prevent NEC, then the risk of necrotizing enterocolitis may be reduced, but the short-term and long-term safety needs to be assessed in large trials and there are unanswered questions regarding dose, duration, and type of probiotic agents
Solution Approach 1:
The patent changes the fundamental parameter from using live probiotic organisms to using oligosaccharides (specifically human milk oligosaccharides and their precursors) that serve as prebiotics. This parameter change eliminates safety concerns associated with live organisms in immunocompromised preterm infants while maintaining the beneficial effect of promoting healthy gut microbiota growth.
Solution Approach 2:
The patent employs oligosaccharides that are stable, easy to manufacture, and can be incorporated into standard infant formula without requiring complex formulation, storage, or administration protocols. This simplifies the overall system compared to probiotics which require careful handling to maintain viability.
2Reliability
If human milk oligosaccharides are used in infant formula, then the prevention of NEC and promotion of gut maturation is achieved, but the complexity of formulating specific oligosaccharide mixtures increases
Solution Approach 1:
The patent extracts and utilizes only the essential protective components from human milk - specifically oligosaccharides and their precursors - without requiring the complete complexity of human milk composition. This allows replication of the beneficial effects in a simplified formula context.
Solution Approach 2:
The oligosaccharide mixture serves multiple functions simultaneously: it acts as a prebiotic to promote beneficial bacteria growth, provides direct gut protection, reduces inflammation, and promotes overall gut maturation. This multi-functionality is achieved through a relatively simple mixture of oligosaccharide types.
3Reliability
If breast feeding is recommended for all infants, then the prevention of NEC and promotion of gut health is maximized, but in some cases breast feeding is inadequate or unsuccessful for medical reasons or the mother chooses not to breast feed
Solution Approach 1:
The patent creates a synthetic copy of the protective factors found in human milk by incorporating oligosaccharides and their precursors into infant formula. This copying allows infants who cannot be breastfed to receive the same protective benefits against NEC and for gut maturation promotion.
4Reliability
If existing probiotic compositions are used, then some reduction in NEC risk may be achieved, but the results are inconsistent and there are unanswered questions regarding dose, duration, and type of probiotic agents
Solution Approach 1:
The patent changes from using probiotics (live organisms) to oligosaccharides (chemical compounds) as the active ingredient. This parameter change eliminates the variability associated with probiotic strain selection, dosing, and duration, providing more consistent and predictable results.
Data Source
AI summary
The invention discloses a composition comprising an oligosaccharide mixture, said oligosaccharide mixture comprising from 40 to 80 wt % of fucosylated oligosaccharide(s), from 10 to 50 wt % of N-acetylated oligosaccharide(s), from 5 to 40 wt % of sialylated oligosaccharide(s) and from 0 to 20 wt % of precursor(s) of human milk oligosaccharide, for use in preventing and/or in treating necrotizing enterocolitis in infants and young children.